<DOC>
	<DOCNO>NCT02514473</DOCNO>
	<brief_summary>To evaluate efficacy safety lumacaftor combination ivacaftor subject age 6 Through 11 year cystic fibrosis ( CF ) , homozygous F508del CF transmembrane conductance regulator ( CFTR ) mutation</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Lumacaftor Combination With Ivacaftor Subjects With CF , Homozygous F508del-CFTR Mutation</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Subjects weigh ≥15 kg without shoe Screening Visit Subjects confirm diagnosis CF Screening Visit . Subjects homozygous F508del CFTR mutation Subjects ppFEV1 ≥70 percentage point adjust age , sex , height Subjects screen LCI2.5 result great equal 7.5 History comorbidity review Screening Visit , opinion investigator , might confound result study pose additional risk administer study drug subject . Any clinically significant laboratory abnormality Screening Visit would interfere study assessment pose undue risk subject Clinically significant abnormality hemoglobin , liver function , renal function Screening Visit . An acute upper low respiratory infection , pulmonary exacerbation , change therapy pulmonary disease within 28 day Day 1 History solid organ hematological transplantation Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>